Science current events, science news articles, research and discoveries.
Top science news articles and science current events stories from the past week.
A visual representation of the most popular science news topics.
Science Current Events Resources
Science Current Events and Science News RSS Feeds
Earth, Life and Space Science News and Current Events RSS Feeds.
|
 |
 |
 |
Abatacept and infliximab improve clinical response over time in methotrexate-refractory RA patients
June 16, 2008
Results from the ATTEST Trial New data presented today at EULAR 2008, the Annual Congress of the European League Against Rheumatism in Paris, France, show that over half of rheumatoid arthritis patients resistant to methotrexate monotherapy improved when either abatacept or infliximab were added to their methotrexate treatment regimen, with positive results sustained up to one year later.
The ATTEST (Abatacept or infliximab versus placebo, a Trial for Tolerability, Efficacy and Safety in Treating RA) trial compared abatacept (~10mg/kg), a selective T cell co-stimulation modulator, with infliximab (3mg/kg), a monoclonal antibody, plus methotrexate (as per each patient's usual dosage, mean dose 16.3-16.6mg) in 431 methotrexate-refractory patients, in a randomised, double-blind, placebo-controlled, 12-month study. Data analyses evaluated the proportion of patients who achieved a 20% improvement in symptoms (as defined by the American College of Rheumatology scale as an ACR20 response) at six months and went on to either improve, maintain or lose this score at twelve months. A similar analysis was conducted in relation to Low Disease Activity Score (LDAS) (DAS28 [CRP] ≤3.2).
ACR Response
Of those patients who achieved an ACR20 response at six months (32 abatacept [ABA] and 27 infliximab [IFX] patients), over a quarter of ABA and IFX patients went on to achieve a 50% improvement (ACR50) at one year (ABA 28.1%, IFX 29.6%). These ACR20 scores were maintained to one year in more ABA than INF patients (95% confidence interval, CI) with over half ABA patients sustained (ABA 59.4%, IFX 44.4%). Furthermore, half as many ABA patients lost their ACR20 score between six months and one year compared to IFX patients (ABA 12.5%, IFX 25.9%).
Low Disease Activity Score
In the LDAS analysis, it was shown that 24 ABA and 23 IFX patients achieved LDAS (but not remission) at six months. Of these patients, over a third ABA (41.7% [22.8, 63.1]) and a quarter IFX patients (28% [12.9, 49.6]) achieved remission at one year. A similar number of ABA (12.5% [3.3, 33.5]) and IFX patients (16% [5.3, 36.9]) retained LDAS to one year, whilst fewer ABA patients (45.8% [26.2, 66.9]) than IFX patients (56% [35.3, 75.0]) lost their LDAS score between six months and one year.
Lead researcher Dr Michael Schiff, of the University of Colorado, USA, commented: "Since RA is a chronic disease, long term treatment efficacy is crucial. Clinical rheumatologists and patients alike need to know the options for maintaining or even increasing treatment responses over time, especially with the growing problem of RA patients becoming refractory, or resistant, to existing treatments. Our study offers significant promise in showing that, where treatment with methotrexate as monotherapy is inadequate, both abatacept and infliximab provide an increasing magnitude of response in measures of RA disease activity, with abatacept yielding slightly higher results across some key ACR and LDAS scores."
European League Against Rheumatism
Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size.
|
 |
Related Infliximab Current Events and Infliximab News Articles Infliximab Current Events and Infliximab News RSS Anti-inflammatory drugs may defeat a treatment-resistant type of cancer Effective drugs for treating a chemotherapy-resistant form of lymphoma might already be on the market according to a study that has pieced together a chemical pathway involved in the disease.
Infliximab may help prevent post-operative Crohn's disease recurrence The administration of infliximab after intestinal resective surgery was found to be effective at preventing endoscopic and histological recurrence of Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.
First international guidelines for treatment of psoriatic arthritis Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it.
Mayo Clinic collaborates to advance Crohn's treatment A study led by Mayo Clinic has found that infliximab (Remicade®) administered alone (monotherapy) or in combination with azathioprine is a more effective treatment for patients with moderate to severe Crohn's disease than azathioprine alone.
The prevalence of hepatitis B virus infection in inflammatory bowel disease patients Patients with IBD have high risk of infection by hepatitis viruses B or C because during the course of their disease, they need blood transfusions, and sometimes surgical and endoscopic procedures for diagnosis and treatment.
'Stuffy nose' mouse: A promise to help treat 31 million with sinusitis Mice with inflamed nasal tissue being tested at a Johns Hopkins laboratory may be unable to tell if something smells bad or good, but their sensory deficit is nothing to turn up a nose at.
New Guidelines for Treating Rheumatoid Arthritis Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB).
New therapeutic targets in the treatment of ulcerative colitis Social, environmental and dietary changes are associated with the changes of disease spectrum in a country. Ulcerative colitis has become a commonly seen disease in China, probably due to extensive consumption of Western foods in recent years.
Infliximab scheduled treatment has proven to be an effective strategy in IBD patients Crohn's disease (CD) and ulcerative colitis (UC) are chronic-relapsing diseases, the clinical courses of which are characterized by periods of remission and periods of acute flare up, determining clinical symptoms which have a strong impact on the quality of life for patients.
Promising drug fails to improve COPD symptoms A promising anti-inflammatory drug failed to improve symptoms of moderate to severe chronic obstructive pulmonary disease, or COPD, in a large, multi-center trial. More Infliximab Current Events and Infliximab News Articles
|
 |
|
|
Infliximab approved for severe plaque psoriasis.(News): An article from: Skin & Allergy News
by Elizabeth Mechcatie (Author)
This digital document is an article from Skin & Allergy News, published by Thomson Gale on November 1, 2006. The length of the article is 652 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Infliximab approved for severe plaque psoriasis.(News) Author: Elizabeth Mechcatie Publication: Skin & Allergy News (Magazine/Journal) Date: November 1, 2006 Publisher: Thomson Gale Volume: 37 Issue: 11 Page: 5(1)
Distributed by Thomson...
|
|
|
Infliximab sparks remission in refractory urticaria patients.(DERMATOLOGIC THERAPY): An article from: Skin & Allergy News
by Bruce Jancin (Author)
This digital document is an article from Skin & Allergy News, published by International Medical News Group on June 1, 2009. The length of the article is 392 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.
Citation Details Title: Infliximab sparks remission in refractory urticaria patients.(DERMATOLOGIC THERAPY) Author: Bruce Jancin Publication: Skin & Allergy News (Magazine/Journal) Date: June 1, 2009 Publisher: International Medical News Group Volume: 40 Issue: 6 Page: 29(1)
Distributed by Gale, a part of Cengage...
|
|
|
Infliximab earning place as Crohn's first-line Rx.(Report): An article from: Internal Medicine News
by Damian McNamara (Author)
This digital document is an article from Internal Medicine News, published by International Medical News Group on November 15, 2008. The length of the article is 672 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.
Citation Details Title: Infliximab earning place as Crohn's first-line Rx.(Report) Author: Damian McNamara Publication: Internal Medicine News (Magazine/Journal) Date: November 15, 2008 Publisher: International Medical News Group Volume: 41 Issue: 22 Page: 29(1)
Article Type: Report
Distributed by Gale, a part of Cengage...
|
|
|
Coccidioidomycosis pneumonia in a nonendemic area associated with infliximab.(Case Report)(Case study): An article from: Southern Medical Journal
by Mahmood Dweik (Author), Bruce A. Baethge (Author), Alexander G. Duarte (Author)
This digital document is an article from Southern Medical Journal, published by Thomson Gale on May 1, 2007. The length of the article is 1440 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Coccidioidomycosis pneumonia in a nonendemic area associated with infliximab.(Case Report)(Case study) Author: Mahmood Dweik Publication: Southern Medical Journal (Magazine/Journal) Date: May 1, 2007 Publisher: Thomson Gale Volume: 100 Issue: 5 Page: 517(2)
Article Type: Case study
Distributed by Thomson...
|
|
|
Pustular psoriasis induced by infliximab.(CASE REPORTS): An article from: Journal of Drugs in Dermatology
by Marzieh Thurber (Author), Adrienne Feasel (Author), John Stroehlein (Author), Sharon R. Hymes (Author)
This digital document is an article from Journal of Drugs in Dermatology, published by Journal of Drugs in Dermatology, Inc. on July 1, 2004. The length of the article is 1171 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Pustular psoriasis induced by infliximab.(CASE REPORTS) Author: Marzieh Thurber Publication: Journal of Drugs in Dermatology (Refereed) Date: July 1, 2004 Publisher: Journal of Drugs in Dermatology, Inc. Volume: 3 Issue: 4 Page: 439(2)
Distributed by Thomson...
|
|
|
Infliximab associated new-onset psoriasis.(CASE REPORTS): An article from: Journal of Drugs in Dermatology
by David R. Adams (Author), Tamy Buckel (Author), Jennifer A. Sceppa (Author)
This digital document is an article from Journal of Drugs in Dermatology, published by Thomson Gale on February 1, 2006. The length of the article is 626 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Infliximab associated new-onset psoriasis.(CASE REPORTS) Author: David R. Adams Publication: Journal of Drugs in Dermatology (Magazine/Journal) Date: February 1, 2006 Publisher: Thomson Gale Volume: 5 Issue: 2 Page: 178(2)
Distributed by Thomson...
|
|
|
Infliximab quells psoriatic arthritis symptoms.(Rx): An article from: Internal Medicine News
by Bruce Jancin (Author)
This digital document is an article from Internal Medicine News, published by International Medical News Group on August 15, 2004. The length of the article is 765 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Infliximab quells psoriatic arthritis symptoms.(Rx) Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: August 15, 2004 Publisher: International Medical News Group Volume: 37 Issue: 16 Page: 29(1)
Distributed by Thomson...
|
|
|
Infliximab found effective in Pediatric Crohn's.(Clinical Rounds): An article from: Pediatric News
by Sherry Boschert (Author)
This digital document is an article from Pediatric News, published by Thomson Gale on April 1, 2006. The length of the article is 660 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Infliximab found effective in Pediatric Crohn's.(Clinical Rounds) Author: Sherry Boschert Publication: Pediatric News (Magazine/Journal) Date: April 1, 2006 Publisher: Thomson Gale Volume: 40 Issue: 4 Page: 51(1)
Distributed by Thomson...
|
|
|
No shortage of treatment options for IBD: use azathioprine before infliximab. (Clinical Rounds).(inflammatory bowel disease ): An article from: Family Practice News
by Bruce Jancin (Author)
This digital document is an article from Family Practice News, published by International Medical News Group on June 1, 2003. The length of the article is 1075 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: No shortage of treatment options for IBD: use azathioprine before infliximab. (Clinical Rounds).(inflammatory bowel disease ) Author: Bruce Jancin Publication: Family Practice News (Magazine/Journal) Date: June 1, 2003 Publisher: International Medical News Group Volume: 33 Issue: 11 Page: 27(1)
Distributed by Thomson...
|
|
|
Serial-Dose Infliximab Controls Crohn's Disease.(Remicade): An article from: Internal Medicine News
by Mitchel L. Zoler (Author)
This digital document is an article from Internal Medicine News, published by International Medical News Group on July 1, 2001. The length of the article is 819 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details Title: Serial-Dose Infliximab Controls Crohn's Disease.(Remicade) Author: Mitchel L. Zoler Publication: Internal Medicine News (Magazine/Journal) Date: July 1, 2001 Publisher: International Medical News Group Volume: 34 Issue: 13 Page: 20
Article Type: Product/Service Evaluation
Distributed by Thomson...
|
|